Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE: Conbercept in Neovascular AMD
NCT01242254Phase 2Completed
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Aug 2009
- Primary completion
- Mar 2010
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of conbercept in neovascular age-related macular degeneration (NVAMD), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Started Aug 2009; status: completed.
02
Drugs
conbercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01242254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242254.